15 February 2024 - Diamyd Medical announced today that the US FDA has granted fast track designation for Diamyd (rhGAD65/alum) that is being investigated to improve glycemic control in recently diagnosed stage 3 type 1 diabetes patients with the genotype HLA DR3-DQ2.

In clinical trials, Diamyd has demonstrated the potential to specifically and safely modulate the immune system's response against pancreatic beta cells, aiming to halt or slow the disease's progression.

Read Diamyd Medical press release